Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miglustat in Chinese NPC patients
NCT03910621Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of miglustat in Niemann-Pick disease type C (NPC), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in Horizontal Saccadic Eye Movements at 52 weeks. Started Apr 2020; status: completed.
02
Drugs
miglustat
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT03910621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910621.